Leap Therapeutics (LPTX) Management is Considering New Indications for DKN-01 - Mizuho Securities
Tweet Send to a Friend
Mizuho Securities analyst Mara Goldstein reiterated a Buy rating and $6.00 price target on Leap Therapeutics (NASDAQ: LPTX) after speaking ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
